Introduction
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), an ALK-negative ALCL associated with textured breast implants, was first recognized in 1997 [1]. The lifetime prevalence of BIA-ALCL is 33 per 1 million persons with textured breast implants [2]. Most patients have excellent outcomes following surgical resection alone. However, in rare cases, BIA-ALCL invades through the capsule and spreads beyond the breast parenchyma to regional lymph nodes requiring systemic chemotherapy [3]. Here, we report a case of aggressive chest wall invasive BIA-ALCL which was successfully treated with a combination of surgery, chemotherapy, radiation, and stem cell transplant. The ideal treatment approach to chest wall invasive BIA-ALCL remains unclear, and this case highlights the need for consensus to optimally manage chest wall invasive BIA-ALCL.

2. Case Presentation
A 51-year-old female with history of bilateral retropectoral silicone breast implants placed in 1996 presented with a two-month history of progressively enlarging right breast...
Imaging including ultrasound and MRI showed a large infiltrative mass involving the right medial chest wall musculature with right axillary adenopathy along with a peri-implant fluid collection. Ultrasound guided biopsy of right chest wall mass in November 2019 showed a CD30-positive, ALK-negative ALCCL which was negative for DUSP22 and TP63 gene rearrangements (Figure 1). Staging PET-CT showed a dominant, coalescent, and infiltrative 13 × 10 × 20 centimeter mass centered in the right anterior chest wall with extension into the pleural/extrapleural compartment along with involvement of regional lymph nodes and osseous invasion of the ribs consistent with advanced disease (Figure 2(a)). She was started on neoadjuvant chemotherapy with CHP-BV (cyclophosphamide, doxorubicin, prednisone, and brentuximab vedotin) and completed 6 cycles in May 2020 achieving a complete metabolic response. In July 2020, she underwent an anterior thoracotomy with resection of the right chest wall tumor, as well as ribs 3–5, partial sternectomy, en bloc removal of the right breast implant, right chest wall reconstruction with mesh/bone cement, thymectomy, serratus advancement flap, and adjacent tissue transfer. Her postoperative course was complicated by chest wall incision necrosis requiring debridement, washout and tissue transfer. Pathologic evaluation revealed viable residual tumor in the sternum, thymus, right anterior chest wall and lymph node samples. She went on to receive 36 Gy of radiation in 1.8 Gy fractions which she completed in November 2020. Restaging PET showed a complete metabolic response with SUVmax 3.9 and a Deauville score of 3 (Figure 2(b)). This was followed by consolidative auto-SCT in February 2021 with abbreviated BEAM where she received 50% of the conditioning regimen (carmustine 300 mg/m² × 1 day, etoposide 200 mg/m² × 2 days, cytarabine 200 mg/m² × 2 days, and melfalan) due to compliance issues. She engrafted well with no complications post auto-SCT. Three months post auto-SCT, she was started on maintenance BV which was stopped after 12 cycles due to worsening neuropathy. She is currently doing well about a year post auto-SCT with no evidence of active disease.

3. Discussion

ALCL is a rare T-cell lymphoma accounting for only 6% of all breast lymphomas [4]. The pathogenesis of BIA-ALCL is not well defined. It has been postulated T-cell activation due to sustained chronic inflammation mediated by a higher bacterial load associated with highly textured implants may be associated with development of T-cell malignancies [5]; however, no specific bacterial species have been found to predispose to BIA-ALCL [6]. In contrast to other ALCCLs, BIA-ALCL are typically triple negative, negative for underlying ALK, DUSP 22, and TP63 mutations. Activating mutations such as JAK1 and STAT3 have been implicated in excess expression of T-cell associated cytokines, notably, IL-6, TGF-β, and IL-10 along with activation of the JAK/STAT signaling pathways leading to accelerated division of lymphocytes predisposing to malignant changes. Further studies are being performed to determine if biomarkers such as SATB1 and JunB could be precursors to development of BIA-ALCL in an effort to identify these patients earlier to initiate treatment [7]. The median time to development of BIA-ALCL is 9 years with a wide range from 2 to 32 years [8]. Although the most common presentation is a peri-implant effusion, 30% of patients present with a palpable breast mass and up to 20% develop lymphadenopathy. 83% of BIA-ALCL patients are diagnosed at stage I and only 7% present with stage IV disease. The majority of patients with BIA-ALCL presenting with early-stage disease are known to have excellent prognosis. Complete capsulectomy along with removal of implant and all evidence of disease has shown improved event free and overall survival in BIA-ALCL [9]. On the other hand, those presenting with a mass tend to have lower survival and increased risk of death. In patients with advanced disease, NCCN guidelines recommend using a combination of chemotherapy (anthracycline-based chemotherapy regimens such as CHOP or CHOP+/- radiation, BV in combination with frontline chemotherapy has shown complete response rate of 92% with overall response rate of 100% [10] in CD30-positive peripheral T-cell lymphomas. In fact, BV in combination with systemic chemotherapy was approved for frontline treatment of systemic ALCL and CD30 positive peripheral T-cell lymphomas following an overall survival benefit when compared to chemotherapy alone [11]. Case reports of BV as monotherapy has also shown durable response in both limited and advanced stage BIA-ALCL in those unable to receive anthracycline based therapy. [12, 13].

However, the optimal management approach to advanced disease remains yet to be determined. There are no prospective trials to guide the management of patients with disseminated disease. Most therapies have been extrapolated from the treatment experience of primary cutaneous and systemic ALCL. In a recent review, 39 patients diagnosed with advanced BIA-ALCL showed higher frequency of limited surgery, chemotherapy, salvage chemotherapy, external beam radiation therapy, and autologous stem cell transplantation when compared with a control group of early-stage BIA-ALCL. The rate of definitive surgery was lower as well as the time to surgery prolonged in advanced disease [14]. While delay in surgery is associated with inferior outcomes, the precise timing of surgery is unclear especially in those with aggressive chest wall invasive disease who may require neoadjuvant chemotherapy to help achieve improved surgical margins and better response rates. Coombs et al. [15] reported two such aggressive chest wall invasive BIA-ALCL cases who were successfully treated with a combination of neoadjuvant chemotherapy followed by chest wall resection and composite reconstruction for residual disease after systemic treatment. This data suggests that chest wall invasive disease may warrant a multimodality approach for improved response rate including use of neoadjuvant chemotherapy prior to definitive surgery. In fact, chest wall infiltration is a critical prognostic factor in BIA-ALCL influencing the possibility of performing a surgical radical tumor extirpation [16]. These uncommon neoplasms also represent a clinical challenge for surgeons as incorrect diagnosis, incomplete resection and unsuccessful
Figure 1: Right axillary lymph node biopsy. (a) Proliferation of large, atypical cells with irregular nuclear contours, vesicular chromatin, and moderately abundant eosinophilic cytoplasm, with background small lymphocytes and eosinophils. (b) Proliferation of large, atypical cells alternating with areas of necrosis. (c) Lymphoma cells stain positive for CD30. (d) Lymphoma cells stain negative for ALK. Right chest wall mass biopsy with (e) large lymphoma cells within background fibrosis, small lymphocytes, and eosinophils (f) with associated adjacent necrosis (g) with lymphoma cells staining positive for CD30.
reconstruction of thoracic wall defects have resulted in high rates of perioperative morbidity and mortality [17]. Globally, this highlights the need for definitive consensus regarding surgery and systemic therapy. Radiation for BIA-ALCL is mostly recommended for incomplete resection or residual disease though long-term toxicity to heart and lungs is unknown. Data on stem cell transplant in BIA-ALCL are limited. Collins et al. [14] reported that 8/39 (20.5%) advanced BIA-ALCL patients underwent an auto-SCT. Most of them had relapsed or refractory cases. 7/8 (87.5%) who underwent auto-SCT remain in CR, the longest follow-up to date being 120 months.

There are some limitations in our case report. Firstly, the factors contributing to extensive chest wall involvement in our patient are unknown. It would be interesting to coalesce larger number of advanced disease cases to determine whether lactate dehydrogenase (LDH) and other potential biomarkers such as beta-2-microglobulin (B2M) retain predictably for chest wall expansion. Secondly, the lack of genomic sequencing restricts our ability to correlate our patient presentation with aggressive genomic features. Despite this, our case demonstrates remarkable benefit of neoadjuvant chemotherapy prior to surgery, upfront consolidation with stem cell transplant followed by CD30 monoclonal antibody maintenance for advanced chest wall invasive BIA-ALCL. This observation is particularly of interest given the known hyper-progression phenomena previously associated with rapid chest wall involvement in the context of indolent disease when partially excised although that was not our patient’s case. In near future, investigation of disease predictors and mutational signature for aggressive BIA-ALCL could assist in identification of hyper-progression cases. Most of screening continues to rely on routine mammogram in asymptomatic patients. Additionally, there is no known intervention to reduce the risk of aggressive disease. It is important to detect early seroma development to perform ultrasound/MRIs to guide aspiration of effusion. T-cell hyperplasia linked with bacterial biofilms is associated with BIA-ALCL suggesting that reducing infection risk, early detection of capsular contraction can reduce the activation of lymphocytes and possible conversion to BIA-ALCL [18]. Our case highlights the need to determine the optimal timing for surgical intervention as well as consensus regarding treatment paradigm for this uncommon group of patients with aggressive chest wall invasive BIA-ALCL. To date, several unresolved questions remain, which include as follows: (1) would aggressive chest wall invasive cases benefit from consolidation with auto-SCT upfront? (2) Is there a role for maintenance therapy in BIA-ALCL? Finally, our case reinforces the concept that maintenance BV after auto-SCT may improve the outcome of patients diagnosed with T-cell lymphomas [19] and should be considered in aggressive chest wall invasive disease to reduce recurrence. Ultimately, cooperative large-scale studies may assist in determining best therapy for aggressive chest wall invasive BIA-ALCL.

4. Conclusion

The treatment paradigm for chest wall invasive BIA-ALCL is not well delineated. Our case here supports the use of a multimodality approach including use of neoadjuvant chemotherapy followed by upfront consolidation with stem cell transplant followed by CD30 monoclonal antibody maintenance.
chemotherapy, surgery, radiation, consolidation with stem cell transplant, and maintenance therapy post transplant for this aggressive variety of BIA-ALCL. Further research looking into the predictors of aggressive disease is much needed. Future studies with randomized control trials will help develop an evidence-based algorithm for this rare type of BIA-ALCL.

Data Availability
No data were used to support this study.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
The authors would like to thank the patient for providing consent for publication of this case report.

References
[1] J. A. Keech and B. J. Creech, "Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant," Plastic and Reconstructive Surgery, vol. 100, no. 2, 1997.
[2] E. L. Doren, R. N. Miranda, J. C. Selber et al., "U.S. Epidemiology of breast implant–associated anaplastic large cell lymphoma," Plastic and Reconstructive Surgery, vol. 139, no. 5, pp. 1042–1050, 2017.
[3] A. E. Quesada, L. J. Medeiros, M. W. Clemens, M. C. Ferrufino-Schmidt, S. Pina-Oviedo, and R. N. Miranda, "Breast implant-associated anaplastic large cell lymphoma: a review," Modern Pathology, vol. 32, no. 2, pp. 166–188, 2019.
[4] S. S. Talwalkar, R. N. Miranda, J. R. Valbuena, M. J. Routhbort, A. W. Martin, and L. J. Medeiros, "Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms," The American Journal of Surgical Pathology, vol. 32, no. 9, pp. 1299–1309, 2008.
[5] J. L. Jones, A. M. Hanby, C. Wells et al., "Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management," Histopathology, vol. 75, no. 6, pp. 787–796, 2019.
[6] J. N. Walker, B. M. Hanson, C. L. Pinkner et al., "Insights into the microbiome of breast implants and periprosthetic tissue in breast implant-associated anaplastic large cell lymphoma," Scientific Reports, vol. 9, no. 1, Article ID 10393, 2019.
[7] M. E. Kadin, A. Deva, H. Xu et al., "Biomarkers provide clues to early events in the pathogenesis of breast implant-associated anaplastic large cell lymphoma," Aesthetic Surgery Journal, vol. 36, no. 7, pp. 773–781, 2016.
[8] R. N. Miranda, T. N. Aladily, H. M. Prince et al., "Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients," Journal of Clinical Oncology, vol. 32, no. 2, pp. 114–120, 2014.
[9] M. W. Clemens, L. J. Medeiros, C. E. Butler et al., "Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma," Journal of Clinical Oncology, vol. 34, no. 2, pp. 160–168, 2016.
[10] M. A. Fanale, S. M. Horwitz, A. Forero-Torres et al., "Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas," Blood, vol. 131, no. 19, pp. 2120–2124, 2018.
[11] S. Horwitz, O. A. O’Connor, B. Pro et al., "Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial," Lancet, vol. 393, no. 10168, pp. 229–240, 2019.
[12] J. P. Alderuccio, A. Desai, M. M. Yepes, J. R. Chapman, F. Vega, and I. S. Losssos, "Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma," Clinical Case Reports, vol. 6, no. 4, pp. 634–637, 2018.
[13] A. Stack, N. Ali, and N. Khan, "Breast implant-associated anaplastic large cell lymphoma: a review with emphasis on the role of brentuximab vedotin," Journal of Cell Immunology, vol. 2, no. 3, pp. 80–89, 2020.
[14] M. S. Collins, R. N. Miranda, L. J. Medeiros et al., "Characteristics and treatment of advanced breast implant-associated anaplastic large cell lymphoma," Plastic and Reconstructive Surgery, vol. 143, 2019.
[15] D. M. Coombs, R. Aliotta, D. Jagadeesh, D. Raymond, and R. Isakov, "Breast implant-associated anaplastic large cell lymphoma with invasive chest wall masses," Annals of Plastic Surgery, vol. 87, no. 4, pp. 409–414, 2021.
[16] A. Campanale, A. Di Napoli, M. Ventimiglia et al., "Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients," European Journal of Cancer, vol. 148, pp. 277–286, 2021.
[17] G. Q. Lin, Y. Q. Li, L. J. Huang, F. Y. Luo, H. H. Jiang, and W. J. Luo, "Chest wall tumors: diagnosis, treatment and reconstruction," Experimental and Therapeutic Medicine, vol. 9, no. 5, pp. 1807–1812, 2015.
[18] P. A. Thompson and H. M. Prince, "Breast implant-associated anaplastic large cell lymphoma: a systematic review of the literature and mini-meta analysis," Curr Hematol Malig Rep, vol. 8, no. 3, pp. 196–210, 2013.
[19] J. M. Vose, "Outcomes for PTCL: which pathway to success?" Blood, vol. 137, no. 19, pp. 2570–2571, 2021.